However, previous studies have already demonstrated that other biological motifs are relevant for the prognosis of ER- and HER2+ carcinomas, particularly an immune cell signature[27] which is best represented by IGKC as a biomarker[38]. The gene discussed is ERBB2; the disease is carcinoma.